在HBeAg阴性慢性乙型肝炎患者中,HBsAg血清的预测因子是用核类相应物加聚乙烯糖醇干扰素治疗的
Yan Peng1, Mingzhe Ma1, Ting Liu2
1Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Frontiers in medicine
|January 23, 2025
概括
结合治疗与核酸类似物 (NA) 和聚乙烯糖醇干扰素 (PEG-IFN) 显著改善了慢性乙型肝炎 (CHB) 患者的乙型肝炎表面抗原 (HBsAg) 清除. 氨酸氨基转移酶 (ALT) 变化预测治疗疗效.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 慢性乙型肝炎 (CHB) 影响全球数百万人,对乙型肝炎表面抗原 (HBsAg) 清除的治疗选择有限.
- 聚乙烯甘醇干扰素 (PEG-IFN) 与核酸相似物 (NA) 结合提供了HBsAg损失的潜力,但确定最佳候选者至关重要.
研究的目的:
- 评估NA和PEG-IFN联合治疗与单独使用NA治疗CHB的疗效.
- 在接受联合治疗的患者中确定HBsAg清除的预测因子.
主要方法:
- 对122名CHB患者的回顾性分析,他们接受了48周的单独NA或NA加PEG-IFN治疗.
- 用单变量和多变量分析来确定疗效预测因素.
主要成果:
- 与单独使用NA组相比,NA加PEG-IFN组的HBsAg清除率 (40.98%) 显著更高.
- 乙型肝炎表面抗原 (HBsAg) 水平,24周的阿兰氨转移酶 (ALT) 和从基线到24周的ALT变化 (dALT2) 被证实是疗效的独立预测指标.
结论:
- 结合NA和PEG-IFN疗法对于CHB患者来说是一个有价值的治疗方案.
- 从基线到第24周的ALT变化 (dALT2) 是接受联合治疗的CHB患者治疗反应的新型独立预测因子.
更多相关视频
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
2.8K
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.1K
相关概念视频
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
